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Abstract: A seven-month-old male collie was brought to our clinic with complaints of exhaustaion and fatigue for the past month,
inability to stand on its hind legs, loss of voice and anorexia for the past week. In clinical examination, increase in heart frequency,
difficulty in lifting the head, tetraparesis, regurgitation and urinary incontinence were observed. MG was suspected and 0.05 mg/kg
i.m. neostigmine methylsulfate was given for clinical diagnosis. A positive response was seen within 30 minutes of drug application.
The same drug was administered 3 hours later and the same positive clinical findings were observed. The disease was diagnosed as
MG. The serum AChR antibody concentration was determined to be 0.03 nmol/l. Pyridostigmine bromide was used for four weeks
and prednisolone was used for two weeks. The patient was able to walk normally after 15 days and had a good appetite. The dog
was sent back home in good health six weeks later and the disease did not relapse for more than two years.
Key Words: Myasthenia gravis, dog.

Bir Köpekte Myasthenia Gravis
Özet: Yedi aylık, erkek Collie köpek son bir ayda kas zayıflığı belirtileri, son bir hafta içinde arka ayakları üzerinde duramama, sesin
kaybolması ve iştahsızlık şikayetleri ile kliniğimize getirildi. Yapılan klinik muayanesinde, kalp frekansında artış, başını güçlükle
kaldırdığı, ayağa kalkamadığı, regürgitasyon ve idrarını tutamadığı gözlendi. MG’dan şüphelenildi ve klinik tanı için 0.05 mg/kg
neostigmine methysulfate’ın i.m. yolla verildi. Bu ilacın verilmesinden 30 dak. içinde klinik yanıt alındı. Üç saat sonra aynı ilaç tekrar
edildi, aynı klinik bulgular gözlendi. Hastalık MG olarak değerlendirildi. Serum AChR antikor konsantrasyonu 0.03 nmol/l olarak
saptandı. Pyridostigmine bromid dört hafta ve prednisolone iki hafta kullanıldı. Hasta 15 gün sonra normal olarak yürüdü ve iyi bir
iştaha sahip oldu. Köpek altı hafta sonra sağlıklı olarak evine gönderildi. Bu hastalık iki yılı aşkın sürede nüks etmedi.
Anahtar Sözcükler: Myasthenia gravis, köpek.

Introduction
Myasthenia Gravis (MG) is a neuromuscular disease
characterized by muscle weakness and fatigue (1, 2). MG
occurs in both acquired and congenital forms (3). It has
been reported that although acquired MG in dogs is seen
to begin in animals from eight weeks to eleven years of
age, it is usually observed between the ages of one and
eight years (3, 4). The clinical symptoms of congenital MG
have been reported to arise in 6-8 week-old puppies (3).
The cause of MG is the reduction in the number of
functional acetylcholine receptors in the postsynaptic
membrane of the neuromuscular junctions (1, 5).
Acquired MG is characterized by the presence of
autoantibodies against acetylcholine receptors (1, 2).
Although the cause of autoantibodies is not exactly
known, it has been suggested that the thymus may play a
role (1, 2). Thymoma has been observed in some cases
(6, 7, 8); however, autoimmunity signs have been
reported to be absent in congenital MG (1, 3).

MG is a disorder which appears with exercise and is
characterized by fatigue in skeletal muscles (4, 5). Most
patients show clinical such signs as dysphagia, salivation
and megaesophagus along with regurgitation. It has been
reported that, as a result of clinical symptoms, aspiration
pneumonia can occur (3). According to some authors (3,
4) the definitive diagnosis for MG can be made by its
reply to cholinesterase drugs, electrodiagnostics and the
presence of antiAChR antibodies in the sera of the
patients. Treatments for MG in dogs have been reported
to be mainly cholinesterases and immunosupressive drugs
(1, 4).
Case Report
A seven-month-old male Collie weighing 15 kg was
brought to our clinic with complaints of exhaustion and
fatigue for the past month and inability to stand on its
back legs, loss of voice and anorexia for the past week.
The following parameters were recorded in the first
physical examination: heart frequency 104-108/minute,
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respiration frequency 28-32/minute, temperature
38.2°C, total leukocyte count 7300/mm3, hematocrit
value 38%, creatin phosphokinase 166 U/L and aspartate
aminotransferase 13.3 U/L.
The dog was hospitalized. Over two days the
following symptoms were observed: inability to stand
(tetraparesis), difficulty in lifting the head, increase in
heart frequency, regurgitation and urinary incontinence
(Figure 1). Clinical findings were evaluated and, on the
assumption that the disease might be MG, neostigmine
methylsulfate (Prostigmine amp., Roche) was given at a
dose of 0.05 mg/kg IM, and a positive clinical reply
occured within 30 minutes. Three hours later, the drug
was readministered (0.85 mg) and the same findings
were obtained (Figure 2). The disease was diagnosed as
MG. Following drug use, heart frequency decreased and
defecation was observed; however, cholinergic crisis
findings such as salivation, vomiting and diarrhea did not
occur. Although megaesophagus was suspected in
thoracal radiographs, no signs of thymoma or aspiration
pneumonia were observed. The following day,
neostigmine was administered in respective doses of 0.85
mg, 1mg, 1mg and IM. On the third day, as there was
there no longer any risk of regurgitation, oral
administration of pyridostigmine bromide (Mestinon dr.,
Roche) with the effect of long-term anticholinesterase
was begun. It was administered 2 mg/kg twice daily for
two weeks, and gradually decreased to 10 mg (0.64
mg/kg) over the next two weeks. Two days after
pyridostigmine bromide treatment was started,
prednisolone was administered twice daily at a dosage of

2 mg/kg IM and, over a period of weeks, was decreased
to 1.5 mg/kg once a day. After this, prednisolone
treatment was discontinued.
It was observed that within two days the dog was able
to stand on its forelegs. Between the second an fifth day
the dog could drag its hindlegs and was able to consume
a liquid diet. On the fifth day, the dog was able to control
its urination and defecation, and between the seventh and
fourteenth days could walk with support and stand up on
its own to defecate. The dog barked for the first time on
the ninth day. On the fifteenth day it walked normally and
its appetite returned. Two week after the pyridostigmine
treatment was discontinued, the dog was examined in our
clinic. Although treatment had stopped, the dog began
running. No relapse of the disease was observed as much
as two years after the patient was returned to its owners
(Figure 3).
Serum anti-AChR antibody concentrations were
determined at Comp. Neuromusculer Lab, CA, USA.
Serum AChR concentration was 0.03 nmol/l before
treatment and 0.0 nmol/l after treatment.
Discussion
Although the most common findings of MG are
reported to be walking disorders following exercise (1,
4), such symptoms are also seen in peripheral neuropathy
and polymyositis. In these diseases, the walking
abnormalities are continuous, and there is atrophy in the
muscles, and other findings associated with MG are not

Figure 1.
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Apperance of the dog with
myasthenia gravis before
neostigmine methylsulfate
administraiton.
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present (9). In this case, as well as swaying of the
backside after walking, symptoms such as loss of voice,
regurgitation, total inability to stand up and difficulty in
lifting the head were observed.
Although the serum AChR antibody concentration
recorded before the treatment was normal, serum AChR
antibody concentration after treatment was found to
have decreased. However, this serum AChR concentration
was in agreement with those recorded in MG patients by
other researchers (7). According to some investigators
(4, 10), AChR antibodies can be determined in 80 to

Figure 2.

Apperance of the dog with
myasthenia gravis after
neostigmine methylsulfate
administration.

Figure 3.

Nine months after the
treatment, apperance of the
dog.

90% of canine and human patients with acquired MG;
however, no complete correlation has been determined
between a single antibody concentration and the severity
of disease (4). Additionally, suggested explanations of
seronegativity include the following: low titre of high
affinity antibody with all available antibody bound to
receptors, inability of the standard radioimmunoassay to
detect antibodies bound to the α-bungarotoxin site,
antibody present to end-plate determinants other than
the acetylcholine receptor, technical factors affecting test
sensitivity and antigenic differences in acetylcholine
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receptors (10). Receptor antibodies in humans with
thymoma and MG are always positive and are inclined to
have higher concentrations than MG patients without
thymoma (4). Thymoma was not revealed in this dog.
MG requries long-term combination therapy (11).
Cholinesterase inhibitor drugs are the principal agents
used in the management of canine MG (4).
Anticholinesterase drugs inhibit enzymatic hydrolysis of
ACh at the neuromuscular junction, prolonging the
interaction of ACh released at the nerve terminus with the
remaining AChRs, thereby increasing the effective
concentration and duration of the effect of ACh in the
synaptic cleft (1). Although some investigators (7, 11)
have reported using anticholinesterases for a period
between 6 weeks and 6 years, in this case pyridostigmine
bromid was used for only a month.

Corticosteroids have been reported to be widely used
in the treatment of acquired MG (2, 3, 4). The primary
benefical effect of corticosteroids in this disease is related
to supression of initiating aberrant immune response
against acetylcholine receptors (1, 4). It has been
reported that corticosteroids have also been reported to
be successful on their own in the treatment of acquired
MG (12). On the other hand, although myasthenic crisis
and signs of MG during treatment can quickly be cured by
the use of corticosteroids and cholinesterases (2), it has
been reported that corticosteroids cannot be
recommended in all case (1).
In this case, succesfull results were achieved by a
combined treatment trial. Six weeks after being given
both groups of drugs, the dog returned to its home in
good health. The dog was observed for a further two
years and relapse of the illness was seen.
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